AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26255876 — intervention group
Group type: COMPARATOR
Intervention: Nasal septum dysplasia as an etiologic factor for gummy smile.
Number of subjects: 121
Study 23893461 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg) administered in a fed state
Number of subjects: 24
Study 23893461 — intervention group
Group type: COMPARATOR
Intervention: Trametinib (2 mg) administered in a fasted state
Number of subjects: 24
Study 20063106 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid (1 microg/kg of fentanyl intravenously)
Number of subjects: 27
Study 20063106 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 27
Study 18780182 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the positive action program (amount of curriculum delivered and use of program-specific materials)
Number of subjects: 362
Study 18780182 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' attitudes toward the program
Number of subjects: 362
Study 18780182 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' beliefs about SACD
Number of subjects: 362
Study 18780182 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of school climate
Number of subjects: 362
Study 17000959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 microg subcutaneously three times weekly (TIW)
Number of subjects: 560
Study 17000959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 22 microg subcutaneously three times weekly (TIW)
Number of subjects: 560
Study 17000959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially randomized group)
Number of subjects: 560
Study 17000959 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 560
Study 17000959 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 560
Study 12730744 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access DXA scanning (DADS)
Number of subjects: 330
Study 12730744 — intervention group
Group type: COMPARATOR
Intervention: Current system of specialist referral (controls)
Number of subjects: 330
Study 11097538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative morphine (0.1 mg x kg(‐1))
Number of subjects: 70
Study 11097538 — intervention group
Group type: COMPARATOR
Intervention: Postoperative morphine (0.1 mg x kg(‐1))
Number of subjects: 70
Study 8760978 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA plus medical treatment (n = 30)
Number of subjects: 42
Study 8760978 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (control group, n = 32)
Number of subjects: 42
Study 1581268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 16
Study 1581268 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine without epinephrine
Number of subjects: 16
Study 1581268 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pleural infusion of bupivacaine
Number of subjects: 16
Study 1581268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pleural infusion of bupivacaine
Number of subjects: 16
Study 30796054 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Goldmann prism
Number of subjects: 243
Study 30796054 — intervention group
Group type: COMPARATOR
Intervention: Standard Goldmann prism
Number of subjects: 243
Study 29851120 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially group‐function occlusion (PGFO)
Number of subjects: 30
Study 26685154 — intervention group
Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament test
Number of subjects: 67
Study 26685154 — intervention group
Group type: EXPERIMENTAL
Intervention: Static two-point discrimination test
Number of subjects: 67
Study 27129118 — intervention group
Group type: EXPERIMENTAL
Intervention: SFDAC intranasal spray (up to 3,200 µg)
Number of subjects: 0
Study 27129118 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 27129118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22121129 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX (Group 2)
Number of subjects: 269
Study 22121129 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX (Group 3)
Number of subjects: 269
Study 22121129 — intervention group
Group type: EXPERIMENTAL
Intervention: combined Groups 2 and 3
Number of subjects: 269
Study 22121129 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX (Group 1)
Number of subjects: 269
Study 22121129 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 269
Study 22121129 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 1, 2, and 3
Number of subjects: 269
Study 19945102 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with an angular stable interlocking implant (25 patients)
Number of subjects: 50
Study 19945102 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (25 patients)
Number of subjects: 50
Study 17380402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation consisting of an isotonic solution containing polyethylene glycol and simethicone (200 ml given 30 min before capsule, followed by 100 ml of prep and 100 ml of water; additional 100 ml of prep given 45 and 75 min later)
Number of subjects: 9
Study 17380402 — intervention group
Group type: COMPARATOR
Intervention: Control administration of 100 ml of water and no simethicone
Number of subjects: 9
Study 15598683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 50
Study 15598683 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 50
Study 15598683 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 50
Study 15598683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meal
Number of subjects: 50
Study 12150229 — intervention group
Group type: EXPERIMENTAL
Intervention: Actors' perspective taking
Number of subjects: 0
Study 12150229 — intervention group
Group type: COMPARATOR
Intervention: Observers' correspondent inferences
Number of subjects: 0
Study 10434485 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at an average dose of 0.5 mg/kg twice daily
Number of subjects: 91
Study 10434485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 10434485 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 91
Study 8871266 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg twice-a-day
Number of subjects: 69
Study 8871266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 2273545 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 2 mg in 8 ml of normal saline administered epidurally one to two hours before the end of surgery.
Number of subjects: 45
Study 2273545 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administered epidurally at different spinal levels (Th11-12, L2-3, caudal).
Number of subjects: 45
Study 2273545 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administered epidurally.
Number of subjects: 45
Study 6104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidolol (50 mg or 100 mg)
Number of subjects: 15
Study 6104564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30296875 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP pharmacist service
Number of subjects: 104
Study 29969433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS)
Number of subjects: 366
Study 29969433 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 366
Study 27836933 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (starting doses: 160 mg or lower)
Number of subjects: 45
Study 27836933 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (lower dose)
Number of subjects: 45
Study 27836933 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (overall treatment)
Number of subjects: 45
Study 25569710 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective message using affectively laden phrases
Number of subjects: 559
Study 25569710 — intervention group
Group type: COMPARATOR
Intervention: Cognitive message using cognitively laden phrases
Number of subjects: 559
Study 23298394 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced heat therapy (RFHT) for 30-60 seconds
Number of subjects: 100
Study 23298394 — intervention group
Group type: COMPARATOR
Intervention: Intralesional sodium stibogluconate (SSG) injections (50 mg cm(‐2) of lesion, seven injections)
Number of subjects: 100
Study 20659937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (1 ml suspension, 100,000 U/ml, every 8 h)
Number of subjects: 278
Study 20659937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg body weight, every third day)
Number of subjects: 278
Study 20659937 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 278
Study 19074465 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 at 0.2 mg/kg
Number of subjects: 37
Study 19074465 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 at 0.5 mg/kg
Number of subjects: 37
Study 19074465 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 at 0.7 mg/kg
Number of subjects: 37
Study 19074465 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 at all doses
Number of subjects: 37
Study 17685721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering (TAP) for 4 weeks
Number of subjects: 46
Study 17685721 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (DTR) for 4 weeks
Number of subjects: 46
Study 17685721 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 46
Study 15050497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 48
Study 15050497 — intervention group
Group type: COMPARATOR
Intervention: No rescue treatment (Control)
Number of subjects: 48
Study 11720096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (first dose)
Number of subjects: 0
Study 11720096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (second dose, 4 hours after first)
Number of subjects: 0
Study 11720096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (second dose, 24 hours after first)
Number of subjects: 0
Study 11720096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (two doses, 4 hours apart)
Number of subjects: 0
Study 11720096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (two doses, 24 hours apart)
Number of subjects: 0
Study 9340923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen replacement therapy)
Number of subjects: 0
Study 9340923 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 8432115 — intervention group
Group type: EXPERIMENTAL
Intervention: Side Port (SP) cardiac output measurements
Number of subjects: 31
Study 8432115 — intervention group
Group type: COMPARATOR
Intervention: Central Venous Port (CVP) cardiac output measurements
Number of subjects: 31
Study 3479456 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic subgingival irrigation with hydrogen peroxide
Number of subjects: 10
Study 3479456 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic subgingival irrigation with chlorhexidine
Number of subjects: 10
Study 3479456 — intervention group
Group type: COMPARATOR
Intervention: Periodic subgingival irrigation with saline
Number of subjects: 10
Study 3479456 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 10
Study 3479456 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive irrigation with chlorhexidine or hydrogen peroxide
Number of subjects: 10
Study 29446994 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual acupuncture
Number of subjects: 46
Study 29446994 — intervention group
Group type: COMPARATOR
Intervention: Group acupuncture
Number of subjects: 46
Study 28262650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training program + usual care (rehabilitation service)
Number of subjects: 42
Study 28262650 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 42
Study 26016523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal decompression combined with the LimiFlex™ Paraspinous Tension Band (PSB)
Number of subjects: 63
Study 26016523 — intervention group
Group type: COMPARATOR
Intervention: Dorsal decompression only
Number of subjects: 63
Study 23957458 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (operation within 3 days after onset of subarachnoid hemorrhage)
Number of subjects: 99
Study 23957458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate surgery (operation from days 4 to 7)
Number of subjects: 99
Study 23957458 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surgery (operation after day 7)
Number of subjects: 99
Study 23957458 — intervention group
Group type: COMPARATOR
Intervention: All groups (early, intermediate, late surgery)
Number of subjects: 99
Study 21683046 — intervention group
Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College (2-3 hour online course)
Number of subjects: 30
Study 21683046 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 30
Study 18270832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mg and higher)
Number of subjects: 0
Study 18270832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16148277 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive component in 2D catch-up saccade programming based on motion signals
Number of subjects: 0
Study 16148277 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up saccades characterized by large curvature or sudden change of direction
Number of subjects: 0
Study 16148277 — intervention group
Group type: EXPERIMENTAL
Intervention: Position error available first
Number of subjects: 0
Study 16148277 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal slip
Number of subjects: 0
Study 15523305 — intervention group
Group type: EXPERIMENTAL
Intervention: unfractionated heparin or enoxaparin + IIb/IIIa inhibition
Number of subjects: 13800
Study 15523305 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin + IIb/IIIa inhibition
Number of subjects: 13800
Study 15523305 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin + provisional IIb/IIIa inhibition
Number of subjects: 13800
Study 15523305 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors (upstream drug initiation)
Number of subjects: 13800
Study 15523305 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors (during angioplasty only)
Number of subjects: 13800
Study 11096335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive classical conditioning paradigm with odors as unconditioned stimuli and faces as conditioned stimuli
Number of subjects: 24
Study 11096335 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) during habituation, acquisition, and extinction
Number of subjects: 24
Study 11096335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral activity analysis in individually defined cerebral regions
Number of subjects: 24
Study 9308809 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 793
Study 9308809 — intervention group
Group type: COMPARATOR
Intervention: Outpatient hysteroscopy
Number of subjects: 793
Study 8374115 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging (CE-MRI) with intravenous application of a contrast agent (0.1 mmol Gd-DTPA/kg)
Number of subjects: 109
Study 8374115 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging (CE-MRI)
Number of subjects: 109
Study 3330188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400)
Number of subjects: 30
Study 3330188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30661507 — intervention group
Group type: EXPERIMENTAL
Intervention: UPBEAT lifestyle intervention (tailored complex lifestyle intervention focused on improving diet and physical activity)
Number of subjects: 1158
Study 30661507 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 1158
Study 30661507 — intervention group
Group type: EXPERIMENTAL
Intervention: UPBEAT lifestyle intervention
Number of subjects: 1158
Study 28755326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive self-help intervention (62 web-based sessions, reminder e-mails, SMS)
Number of subjects: 85
Study 28755326 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (e-booklet about effects of alcohol)
Number of subjects: 85
Study 28755326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive self-help intervention
Number of subjects: 85
Study 28755326 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 85
Study 26409997 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde brain perfusion
Number of subjects: 121
Study 26409997 — intervention group
Group type: COMPARATOR
Intervention: Antegrade brain perfusion
Number of subjects: 121
Study 26409997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 121
Study 23998546 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-guided strategy
Number of subjects: 600
Study 23998546 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 600
Study 21244474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 31
Study 21244474 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 31
Study 19523206 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI >= 85th percentile, self-perceived as obese, expressed body dissatisfaction
Number of subjects: 448
Study 19523206 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys trying to lose weight
Number of subjects: 448
Study 19523206 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adolescents
Number of subjects: 448
Study 19523206 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls with BMI >= 95th percentile
Number of subjects: 448
Study 19523206 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls with BMI >= 85th percentile
Number of subjects: 448
Study 17802784 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 courses of 7+3+VP‐16 and 5 courses of maintenance therapy (7+3 with thioguanin)
Number of subjects: 354
Study 17802784 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 courses of 7+3+VP‐16, 2 courses 7+3, maintenance‐‐5 courses 7+3 with thioguanin
Number of subjects: 354
Study 17802784 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 courses of 7+3+VP‐16, 2 HAD courses, treatment discontinuation
Number of subjects: 354
Study 17802784 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 354
Study 17802784 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence-free survival
Number of subjects: 354
Study 14749191 — intervention group
Group type: EXPERIMENTAL
Intervention: IDET
Number of subjects: 64
Study 14749191 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 64
Study 11816441 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine for 3 days (CQ, Group I)
Number of subjects: 413
Study 11816441 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulphate for 3 days followed by single-dose sulfadoxine-pyrimethamine (Q3 + SP, Group II)
Number of subjects: 413
Study 11816441 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine for 7 days (Q7, Group III)
Number of subjects: 413
Study 11816441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 20 mg/kg single dose (MEF, Group IV)
Number of subjects: 413
Study 9788686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% azelastine eye-drops
Number of subjects: 151
Study 9788686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% azelastine eye-drops
Number of subjects: 151
Study 9788686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7625341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 sessions of 45 minutes/week at 65% VO2max)
Number of subjects: 30
Study 7625341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 30
Study 7625341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX group)
Number of subjects: 30
Study 7625341 — intervention group
Group type: COMPARATOR
Intervention: Control group (NX group)
Number of subjects: 30
Study 2582767 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Falope ring application
Number of subjects: 100
Study 2582767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 100
Study 2582767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hulka clip application
Number of subjects: 100
Study 2582767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomeroy tubal ligation via minilaparotomy
Number of subjects: 100
Study 952756 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid in aqueous cream or white soft paraffin at concentrations of 2-12% applied to normal skin.
Number of subjects: 23
Study 30311680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 100
Study 30311680 — intervention group
Group type: COMPARATOR
Intervention: Hypopressive exercises (HE)
Number of subjects: 100
Study 28051893 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a standardized patient
Number of subjects: 49
Study 28051893 — intervention group
Group type: COMPARATOR
Intervention: Training on a high-fidelity mannequin
Number of subjects: 49
Study 25078385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (1.5mg/kg bolus at intubation followed by 1.5mg/kg/h infusion until 1h post-surgery)
Number of subjects: 134
Study 25078385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine
Number of subjects: 134
Study 25078385 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 134